相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer
Yan-Song Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South. Korea: A Multicenter Cohort Study
Meihua Jin et al.
ENDOCRINOLOGY AND METABOLISM (2020)
TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma
Claire Bournaud et al.
EUROPEAN JOURNAL OF CANCER (2019)
The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives
Kennichi Kakudo et al.
PATHOLOGY INTERNATIONAL (2018)
Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations
Tae Hyuk Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
The 2017 Bethesda System for Reporting Thyroid Cytopathology
Edmund S. Cibas et al.
THYROID (2017)
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
Young Shin Song et al.
CANCER (2016)
TERT promoter mutations and long-term survival in patients with thyroid cancer
Tae Hyuk Kim et al.
ENDOCRINE-RELATED CANCER (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer
Seo Young Sohn et al.
THYROID (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Recurrence rate in regional lymph nodes in 737 patients with follicular or Hurthle cell neoplasms
Andrej Vogrin et al.
RADIOLOGY AND ONCOLOGY (2016)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Miguel Melo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
Joao Vinagre et al.
VIRCHOWS ARCHIV (2014)
Highly prevalent TERT promoter mutations in aggressive thyroid cancers
Xiaoli Liu et al.
ENDOCRINE-RELATED CANCER (2013)
Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease
Inigo Landa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Progress in molecular-based management of differentiated thyroid cancer
Mingzhao Xing et al.
LANCET (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion
C. J. O'Neill et al.
EJSO (2011)
BRAFK601E Mutation in a Patient with a Follicular Thyroid Carcinoma
Gianmaria Pennelli et al.
THYROID (2011)
Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992-2006
Briseis Aschebrook-Kilfoy et al.
THYROID (2011)
Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution
R. Sciuto et al.
ANNALS OF ONCOLOGY (2009)
Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre
Brian Hung-Hin Lang et al.
ENDOCRINE-RELATED CANCER (2007)
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
MN Nikiforova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)